The University of Texas at Austin · EngineeringTargeted Cancer Therapy Lab
Jennifer A Maynard · Austin, Texas
Research Focus
Dr. Jennifer A. Maynard's lab at the University of Texas at Austin focuses on developing new treatments for aggressive breast cancer, particularly for patients who do not respond to current therapies. Her research aims to create advanced antibody-drug conjugates (ADCs) that target specific protein variants associated with poor patient outcomes. By engineering antibodies to work selectively in the tumor microenvironment, her lab seeks to improve treatment effectiveness while minimizing side effects.
breast cancerantibody-drug conjugatesCD44tumor penetrationaggressive cancerdrug resistancecancer immunotherapyconditional activationpeptide linkers
Research Aims
3AIM 01Develop tumor-selective antibodies targeting CD44 variant 9 (CD44v9).
AIM 02Create novel antibody-drug conjugates (ADCs) using tumor-penetrating peptides.
AIM 03Evaluate the efficacy of ADCs and antibodies in mouse models of HER2-negative breast cancer.
Skills the Lab Values
antibody engineeringcell cultureanimal modelsimmunohistochemistryintravenous injections in miceprotein purificationWestern blotflow cytometryRNA sequencing
Output against the department
Publications133bottom 31% of dept.191st of 278
this lab
most publishedleast published
Citations5.5kbottom 42% of dept.161st of 278
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.